Contineum Therapeutics Inc. - Ordinary Shares - Class A Live Stock Price Today, Share Analysis and Chart

Name: Contineum Therapeutics Inc. - Ordinary Shares - Class A: Is Infosys Ltd. worth buying?
Item: Contineum Therapeutics Inc. - Ordinary Shares - Class A
Rating: 1.47450
Author: Trendlyne DVM scores

about

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIP...

6.16 0.15 (2.50%)

70.90% Fall from 52W High

116.8K

XNAS Volume

XNAS 31 Jul, 2025 1:46 PM (EDT)

Not Eligible

Expensive Valuation

13.0 / 100

Technically Neutral

46.0 / 100

1Yr Price target upside is 375%

4 analysts

Contineum Therapeutics Inc... Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Contineum Therapeutics Inc. - Ordinary Shares - Class A Live Stock Price Today, Share Analysis and Chart

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIP...

70.90% Fall from 52W High

SWOT Analysis

Contineum Therapeutics Inc... Live Price Chart